BioLife Solutions Inc

BioLife Solutions reported second-quarter earnings of $0.04 per share, surpassing the Zacks Consensus Estimate of a loss of $0.01 per share and marking an earnings surprise of 500 percent. Revenue came in at $28.47 million, beating the consensus by 1.48 percent and up from $25.42 million a year ago. The company has now topped consensus EPS and revenue estimates in each of the last four quarters. Shares have gained about 39.8 percent year-to-date, outpacing the S&P 500's 12.8 percent advance.

Payments firm Stripe is in discussions to acquire the AI startup OpenRouter for about $10 billion, headlining a busy week of dealmaking across multiple sectors. IBM intends to acquire quantum-focused research and development institution HRL Laboratories to aid its quantum computing efforts. Brookfield Asset Management agreed to buy battery storage developer Aypa Power for $7 billion including debt, and separately partnered with the Canada Pension Plan Investment Board to acquire LXP Industrial Trust in an all-cash transaction valued at about $5.2 billion including net debt and preferred equity. TE Connectivity announced it is acquiring privately held Astrodyne TDI in a $1.4 billion deal, while Repligen and BioLife Solutions entered into a definitive agreement under which Repligen will acquire BioLife for a total enterprise value of about $1.5 billion, comprised of 64% in Repligen common stock and 36% in cash. Magnolia Oil & Gas agreed to acquire closely held WildFire Energy for $4.06 billion in cash and stock including debt, and raised its quarterly dividend 9% to $0.18 per share. Var Energi agreed to acquire European rival BlueNord in a cash and stock deal valued at about $1.3 billion, creating Europe's largest independent oil and gas producer, while Arcadis rose 12% in Amsterdam trading after a report that the Dutch engineering consultancy received takeover interest from bidders including Canadian peer WSP Global.

Several biotech stocks reached 52-week highs on July 22, 2026, driven by clinical trial updates and acquisition news. Advanced Biomed shares surged over 73% to $18.73 after reporting a first-quarter net income of $5.98 million and disclosing a securities purchase agreement to acquire Accellent Technologies for approximately $1 million. BioLife Solutions rose over 6% to $31.49 following the announcement that Repligen would acquire the company for a total enterprise value of about $1.5 billion. Forte Biosciences gained over 11% to $56.84 after reporting positive Phase 1 vitiligo trial results for its lead product FB102, which is also in Phase 2 for celiac disease. Silence Therapeutics climbed over 9% to $11.90 as it prepares to begin a Phase 3 trial for its siRNA candidate Zerlasiran in high-risk atherosclerotic cardiovascular disease. LB Pharmaceuticals ended up over 10% at $36.59 after announcing that topline results from the Phase 3 NOVA-2 trial of its schizophrenia drug LB-102 would be reported in the first half of 2027, earlier than previously expected.

Repligen Corp. has agreed to acquire BioLife Solutions Inc. in a cash-and-stock deal valued at approximately $1.5 billion. The deal is priced at $31 per share, a 24% premium to BioLife's 90-day volume-weighted average price through July 21, with BioLife shareholders receiving $11.25 in cash and 0.1442 of a Repligen share for each BioLife share. The transaction is expected to close in the fourth quarter of 2026 and be accretive to Repligen's revenue growth, adjusted margins, and adjusted earnings per share, contributing at least $0.05 per share in the first year and $0.25 per share in the second year. Repligen also expects at least $20 million in synergies in year one and $30 million in year two, primarily from public company cost elimination, G&A efficiencies, and manufacturing and supply chain optimization, while retaining more than $300 million in pro forma cash and cash equivalents after closing. Preliminary second-quarter 2026 revenue for Repligen increased about 12% as reported and 13% organically from a year earlier, while BioLife reported preliminary second-quarter revenue of $28.5 million, up 21% from $23.4 million a year earlier.

BioLife Solutions has attracted buyout interest from multiple entities, including bioprocessing technology firm Repligen, according to people familiar with the matter. The company, which serves the cell and gene therapy industry, has added about 18% over the past twelve months. It is not immediately clear how BioLife intends to respond to the potential takeover interest. Following the report late Friday, BioLife shares added about 8% in post-market trading, while Repligen traded flat.

Prosper Stars & Stripes added BioLife Solutions back to its portfolio in the first quarter of 2026, citing a refocused business under CEO Roderick de Greef and a compelling valuation after recent healthcare stock underperformance. The fund noted that de Greef has largely reversed the prior CEO's acquisition strategy, divesting most of those businesses to refocus on high-margin biopreservation media used in cell and gene therapy manufacturing. BioLife Solutions reported first-quarter 2026 total revenue of $27.5 million, a 25% year-over-year increase, and the fund highlighted 20%-plus top-line growth and meaningful margin expansion driving rapid EBITDA growth. The stock closed at $25.58 per share on June 16, 2026, with a market capitalization of $1.29 billion, and was held by 13 hedge fund portfolios at the end of the first quarter, down from 15 in the prior quarter.